Summary
Thirty-two patients with metastatic breast cancer had previously been treated with chemotherapy (in cluding anthracyclines). They were included in a trial to receive 6 g/m3 ifosfamide, mixed with 6 g/m2 mesna in 1000 ml saline infusion, infused over 4 h. Therapy was repeated every 21 days; the dose was reduced by 50%. Twenty-eight patients could be evaluated. An average of 4.2 cycles (range 2–8) was applied. One patient (4%) showed complete remission. Ten patients (36%) had a partial response. Ten patients (36%) experienced SD and the remaining patients (25%) PD. We conclude that high-dose ifosfamide shows activity in this group of pretreated patients and merits further investigation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahmann DL, Bisel HF, Hahn RG (1974) Phase II clinical trial of isophosphamide (NSC 109 724) in patients with advanced breast cancer. Cancer Chemother Rep 58: 861
Bonadonna G, Valagussa P (1983) Chemotherapy of breast cancer: current view and results. Radiat Oncol Biol Phys 9: 279
Brade WP, Herdrich K, Varini M (1985) Ifosfamide-pharmacology, safety and therapeutic potential. Cancer Treat Rev 12: 1
Bryant BM, Jarman M, Ford HT, Smith IE (1980) Prevention of ifosphosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet II: 657
Falkson G, Falkson HC (1976) Further experience with isophosphamide. Cancer Treat Rep 60: 955
Goldin A (1982) Ifosfamide in experimental tumor systems. Semin Oncol 4: 14
Perlow L, Holland J (1984) Chemotherapy of breast cancer. Cancer Med Oncol Tumor Pharmacother 1: 169
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sanchiz, F., Milla, A. High-dose ifosfamide and mesna in advanced breast cancer. Cancer Chemother. Pharmacol. 26 (Suppl 1), S91–S92 (1990). https://doi.org/10.1007/BF00685432
Issue Date:
DOI: https://doi.org/10.1007/BF00685432